Paper Details

  1. Home
  2. Paper Details

Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.

Author: AmadoriSergio, ArceseWilliam, BuccisanoFrancesco, CerrettiRaffaella, De AngelisGottardo, Del PrincipeMaria Ilaria, Di VeroliAmbra, DittoConcetta, Irno-ConsalvoMaria, Lo-CocoFrancesco, MaurilloLuca, NassoDaniela, PanettaPaola, PiciocchiAlfonso, RefrigeriMarco, SarloChiara, SconocchiaGiuseppe, VendittiAdriano

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that a standard-dose (SDAC) chemotherapy regimen resulted in significantly lower levels of leukemia cells (MRD) compared to a high-dose (HDAC) regimen. The study also found that long-term survival was better for those who achieved negative MRD after treatment, particularly with the SDAC regimen. The study suggests that MRD levels could help determine the best dose of chemotherapy and that a standard-dose approach may be more effective in achieving a negative MRD status.
Paper Details　
Original Abstract of the Article :
We assessed by flow cytometry minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) given standard-dose (SDAC) and high-dose ARA-C (HDAC) regimens. Of 163 patients enrolled, 130 (median age, 45 years; range, 18-59 years) qualified for analysis, all achieving complete remission...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/ajh.23893

データ提供：米国国立医学図書館（NLM）

Minimal Residual Disease: A Compass in the Desert of Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a complex and challenging disease, requiring precise treatment strategies. This study investigates the role of minimal residual disease (MRD) as a biomarker for optimizing the dosage of ARA-C, a chemotherapy drug used to treat AML. The authors, like skilled desert navigators, use MRD as a compass to guide treatment decisions, ensuring that patients receive the optimal dose of ARA-C, leading to improved outcomes. Their findings highlight the importance of MRD monitoring in personalizing AML treatment, ensuring a more effective journey through the desert of disease.

Optimizing Treatment: MRD as a Compass for Navigating the Desert of AML

The study reveals that MRD monitoring can effectively guide ARA-C dosing, leading to more frequent MRD negativity and improved survival outcomes for patients with AML. This is like utilizing a compass to navigate a complex desert landscape, ensuring that travelers stay on the right path and reach their destination safely. The authors emphasize the importance of MRD monitoring as a valuable tool for personalizing AML treatment, ensuring patients receive the most appropriate dose of ARA-C.

A New Frontier: MRD-Guided Therapy in the Desert of AML

This research provides compelling evidence for the role of MRD as a biomarker for optimizing ARA-C dosing in AML. The study's findings highlight the importance of personalized medicine in cancer treatment, emphasizing the need for individualized approaches that consider patient-specific factors. This research represents a significant step towards developing more precise and effective treatments for AML, offering hope for a future where we can navigate the complexities of this disease with greater accuracy and success.

Dr.Camel's Conclusion

This study is like finding a reliable compass in the vast desert of acute myeloid leukemia research. It emphasizes the importance of minimal residual disease monitoring in guiding treatment decisions, ensuring that patients receive the optimal dose of ARA-C. By using MRD as a compass, we can navigate the complexities of AML treatment with greater precision and effectiveness, ultimately improving outcomes for patients.

Date :
  1. Date Completed 2015-03-19
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

25377359

DOI: Digital Object Identifier

10.1002/ajh.23893

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.